Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia

Background: To identify risk factors of recurrence in a large series of patients with breast cancer who underwent a nipple-sparing mastectomy (NSM). Patients and methods: Breast-related recurrences and local recurrences (LR) in the breast and the nipple areola complex (NAC) were studied. Cumulative...

Full description

Saved in:
Bibliographic Details
Main Authors: J. Y. Petit, U. Veronesi, R. Orecchia, G. Curigliano, P. C. Rey, E. Botteri, N. Rotmensz, V. Lohsiriwat, M. Cassilha Kneubil, M. Rietjens
Other Authors: Istituto Europeo di Oncologia
Format: Article
Published: 2018
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/14709
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University
Description
Summary:Background: To identify risk factors of recurrence in a large series of patients with breast cancer who underwent a nipple-sparing mastectomy (NSM). Patients and methods: Breast-related recurrences and local recurrences (LR) in the breast and the nipple areola complex (NAC) were studied. Cumulative incidences of events were estimated through competing risk analysis. Multivariate Cox regression models were also applied. Results: We identified 934 consecutive NSM patients duri ng 2002-2007. Median follow-up was 50 months. In 772 invasive carcinoma patients, the rate of LR in the breast and in the NAC was 3.6% and 0.8%, respectively. In the 162 patients with intraepithelial neoplasia, the rate of LR in the breast and in the NAC was 4.9% and 2.9%, respectively. The significant risk factors of LR in the breast for the group A were grade, overexpression/amplification of HER2/neu and breast cancer molecular subtype Luminal B. In group B, the risk factors of LR in the breast and in the NAC were age ( < 45 years), absence of estrogen receptors, grade, HER2/neu overexpression and high Ki-67. Conclusions: The LR rate after NSM in our series was low. Biological features of disease and young age should be taken into account when considering NSM in breast cancer patients. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.